Docoh
Loading...

PGNX Progenics Pharmaceuticals

Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has three commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and oral and subcutaneous formulations of RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which are partnered with Bausch Health Companies Inc.

Company profile

Ticker
PGNX
Exchange
CEO
David W. Mims
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
133379479

PGNX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

7 May 20
17 Apr 21
31 Dec 21
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Jun 20 Maeusli Heinz Christoph Stock Option Common Stock Sale back to company Dispose D No No 5.01 16,393 82.13K 0
19 Jun 20 Maeusli Heinz Christoph Stock Option Common Stock Sale back to company Dispose D No No 5.01 40,000 200.4K 0
19 Jun 20 Benedict Osorio Common Stock Sale back to company Dispose D No No 0 21,202 0 0
19 Jun 20 Benedict Osorio Stock Option Common Stock Sale back to company Dispose D No No 4.77 82,214 392.16K 0
19 Jun 20 Benedict Osorio Stock Option Common Stock Sale back to company Dispose D No No 4.52 90,750 410.19K 0
19 Jun 20 Benedict Osorio Stock Option Common Stock Sale back to company Dispose D No No 6.62 100,000 662K 0
19 Jun 20 Bryce Tenbarge Stock Option Common Stock Sale back to company Dispose D No No 4.77 82,214 392.16K 0
19 Jun 20 Bryce Tenbarge Stock Option Common Stock Sale back to company Dispose D No No 4.52 90,750 410.19K 0
19 Jun 20 Bryce Tenbarge Stock Option Common Stock Sale back to company Dispose D No No 6.62 75,900 502.46K 0
19 Jun 20 Bryce Tenbarge Stock Option Common Stock Sale back to company Dispose D No No 11.32 66,000 747.12K 0

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

9.4% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 1 EXIT
Closed positions 0 1 EXIT
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 8.18M 8.18M
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Farallon Capital Management 8.18M $0 0.0%
Largest transactions
Shares Bought/sold Change
Farallon Capital Management 8.18M 0 0.0%
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: abetted, abide, abstract, adjourned, al, allegedly, Allergan, ample, Area, ARROW, assignment, Attorney, back, banc, begun, Ber, Bernstein, blinded, bound, bridge, brought, bucket, captioned, carcinoma, cell, Centre, China, CI, clarifying, committed, confidentiality, consultant, consulting, curtail, CVR, David, declared, Delaware, Department, der, DGCL, dissenting, DOL, dosimetry, doubled, duration, economy, eleven, Elizabeth, emerging, employment, en, environment, epidemic, exceed, experienced, Fabbio, fiduciary, Fireman, fka, Foerderung, fourth, front, FRS, furlough, furloughed, geography, Goldstone, heightened, Heinz, home, inadequate, inspect, instituted, interruption, IRA, Johnson, jointly, Koln, Krueger, larger, lender, lieu, lump, mAb, Mahmood, mailed, manner, median, merit, misstating, multidisciplinary, NASH, navigate, negotiated, negotiation, Occupational, omitting, OS, outbreak, pandemic, partnership, Patrick, paused, permissible, petition, PGR, Pill, pledge, Power, precautionary, precursor, prejudice, Probe, promotional, promptly, PTAB, purported, putative, quality, quickly, ranging, receptor, recite, reconstitute, reduction, reinstatement, reliance, remanding, remotely, renal, reschedule, rescheduled, rescheduling, rescission, restated, resume, Retirement, saving, shareholder, simplified, simplify, Simplifying, situation, SOX, spread, spreading, St, staggered, stake, standstill, statutory, subsided, sum, summer, suspending, Syed, Thompson, topline, travel, tumor, Universitat, unpatentable, unpredictability, violated, violation, Wang, Wissenschaften, workstation, World, Wuhan, zu, zur
Removed: absence, abstain, acquire, activist, adjustment, advocating, allocating, allocation, antagonist, approach, arising, attempt, attention, attract, belief, BLA, campaign, carry, choose, cold, comparable, comparative, component, composition, comprised, conflict, contest, costly, create, decide, deferred, developing, direction, disruptive, distraction, divert, documented, Easement, eliminating, equivalent, estimating, execute, exist, expand, expedient, factor, formulae, governed, growth, implement, initiate, instability, investor, iodine, knowledge, land, leasing, Likewise, limit, located, MIBG, modified, monoclonal, narrow, nearest, neuroendocrine, open, optional, package, practical, presence, principle, prudent, pursue, pursuing, qualified, qualitative, radiolytic, realize, reconciliation, removed, replace, replicate, reproduce, responding, restructuring, retrospective, rolling, speculative, stage, sublease, substitution, successfully, systematic, tangible, technical, trading, Ultratrace, unanticipated, Union, uniquely, utilized, variation, voting, withhold

Patents

GRANT
Utility
Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination
13 Apr 21
Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and/or tissue.
APP
Utility
Systems and Methods for Artificial Intelligence-based Image Analysis for Cancer Assessment
1 Apr 21
Presented herein are systems and methods that provide for automated analysis of medical images to determine a predicted disease status (e.g., prostate cancer status) and/or a value corresponding to predicted risk of the disease status for a subject.
APP
Utility
Network for Medical Image Analysis, Decision Support System, and Related Graphical User Interface (Gui) Applications
11 Nov 20
Described herein is a platform and supported graphical user interface (GUI) decision-making tools for use by medical practitioners and/or their patients, e.g., to aide in the process of making decisions about a course of cancer treatment and/or to track treatment and/or the progress of a disease.
APP
Utility
Systems and Methods for Automated and Interactive Analysis of Bone Scan Images for Detection of Metastases
28 Oct 20
Presented herein are systems and methods that provide for improved computer aided display and analysis of nuclear medicine images.
APP
Utility
Systems and Methods for Rapid Neural Network-based Image Segmentation and Radiopharmaceutical Uptake Determination
28 Oct 20
Presented herein are systems and methods that provide for automated analysis of three-dimensional (3D) medical images of a subject in order to automatically identify specific 3D volumes within the 3D images that correspond to specific organs and/or tissue.